# Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT04221555** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 68 (actual)

## Conditions studied

- Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Docetaxel, Oxaliplatin, S-1 and Durvalumab
- **DRUG:** Durvalumab and Tremelimumab

## Key facts

- **NCT ID:** NCT04221555
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-13
- **Primary completion:** 2025-04-08
- **Final completion:** 2025-04-08
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04221555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04221555, "Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04221555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*